Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating toripalimab for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma after failure of at least two prio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | Phase 2 | Status: UNKNOWN